Boston Scientific Closes Symetis Acquisition
May 16, 2017—Boston Scientific Corporation announced the close of its acquisition of Symetis SA, a privately held Swiss structural heart company focused on transcatheter aortic valve replacement (TAVR) devices. The companies announced a definitive agreement on March 30, 2017, for Boston Scientific to acquire the Symetis business for $435 million in cash. Symetis will become part of the Boston Scientific Interventional Cardiology division.
With the completion of the acquisition, Boston Scientific will immediately begin selling the Acurate TA transapical valve system and the Acurate neo/TF transfemoral valve system in Europe and other geographies outside of the United States. The Acurate TAVR devices are designed to treat patients with severe and symptomatic aortic valve stenosis who are considered high risk for surgical valve replacement.
Results for the Acurate neo/TF valve in the SAVI-TF Registry were presented as a late breaking clinical trial at the EuroPCR 2017 conference in Paris, France. This European postmarket study assessed the primary endpoint of all-cause mortality at 30 days, as well as the Valve Academic Research Consortium's VARC-2 clinical endpoints through 1 year in 1,000 patients.
Boston Scientific expects to continue the development of the Acurate neo/AS next-generation valve system that is currently in a clinical trial intended to support a future application for European CE Mark approval.